NCT05669820RecruitingPhase 2/3
Antisecretory Factor Glioblastoma Phase 2
Antisecretory Factor During Concomitant and Adjuvant Therapy of Primary Glioblastoma, a Randomised, Prospective and Double Blinded Study
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 20 Dec 2022
- Start date
- 15 Jan 2024
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Peter Siesjö
- Diseases
- Glioblastoma
- NCT number
- NCT05669820
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 300
- From 15 Jan 2024 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Only surgical biopsy
- Only radiotherapy
Other illness
- Egg yolk allergy
Other
- No informed consent
Who the study is looking for
- Pathology verified glioblastoma or astrocytoma grade 4
- Age 18-75 years
- Surgical treatment-resection.
- Scheduled concomitant radiochemotherapy, or only chemotherapy.
- Informed consent
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Skåne University Hospital Coordinator of this site? Confirm its status | Lund | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.